News

Afatinib With Anti-EGF Vaccine Inhibits Tumor Growth for Advanced NSCLC

02/10/2022

Data from the EPICAL trial confirm first line afatinib with anti-EGF vaccination inhibits tumor cell growth, induces a sustained immunogenic effect in patients with advanced NSCLC.

Data from the EPICAL trial...

02/10/2022

Oncology

News

Ivonescimab Projected to Treat EGFR-TKI Resistant, Advanced NSCLC

02/04/2022

A phase 3 trial projects substantial antitumor effect with ivonescimab in patients with EGFR-TKI resistant, advanced, or metastatic NSCLC with an EGFR mutation.

A phase 3 trial projects...

02/04/2022

Oncology

News

Dr Yu Shares Updates of Prevention Efforts in EGFR-Mutant Lung Cancer

10/05/2021

Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.

Helena Yu, MD, discusses updates...

10/05/2021

Oncology

News

Dr Yu Shares Updates of Prevention Efforts in EGFR-Mutant Lung Cancer

10/05/2021

Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.

Helena Yu, MD, discusses updates...

10/05/2021

Oncology

Conference Coverage

Treatment Courses for Third Generation EGFR TKI Resistance in Lung Cancer

10/02/2021

At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting Lyudmila Bazhenova, MD provided an overview of how to manage lung cancer patients with TKI-resistance.

At the virtual 2021 Personalized...

10/02/2021

Oncology

News

EGFR-TKIs Exhibit Safety and Tolerability in Patients with NSCLC

07/22/2021

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.

Epidermal growth factor...

07/22/2021

Oncology

News

Angioinhibition in the Management of NSCLC

12/11/2020

Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.

Edward B. Garon MD, MS, engaged...

12/11/2020

Oncology

News

Osimertinib–Bevacizumab Combo Effective for Metastatic EGFR+ Lung Cancers

07/16/2020

In a study of adults with stage IV EGFR+ lung cancers, first-line combo therapy with bevacizumab and osimertinib was tolerated and yielded efficacy without significant toxicity.

In a study of adults with stage...

07/16/2020

Oncology

News

Bevacizumab–Erlotinib Combo Trumps Erlotinib Monotherapy in EGFR-Positive NSCLC

04/29/2019

Interim phase 3 study findings show that combining bevacizumab therapy with erlotinib improved PFS over erlotinib alone in patients with EGFR-positive NSCLC.

Interim phase 3 study findings...

04/29/2019

Oncology

News

Effect of Smoking History on NSCLC with EGFR Mutation

05/30/2018

A history of smoking may be associated with a higher non-synonymous tumor mutational burden in patients with EGFR mutation–positive non–small-cell lung cancer.

A history of smoking may be...

05/30/2018

Oncology

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology